Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2017

View Archived Issues

Novel pocket-modified vancomycin analogues show potential as durable and potent antibiotics

Mutations in SCN9A gene linked to diabetic neuropathic pain

FDA accepts Rigel Pharmaceuticals' NDA for fostamatinib disodium

Axovant Sciences' nelotanserin obtains FDA fast track designation

Seattle Genetics halting phase III CASCADE study of vadastuximab talirine

Human umbilical cord mesenchymal stem cells evaluated in ischemic cardiomyopathy trial

EC approves biosimilar rituximab from Sandoz

Next generation diarylquinoline TBAJ-587 displays superior potency against tuberculosis

MedImmune introduces a novel anti-FcRII-a antibody

Engineered grafts show esophageal regeneration ability in a large animal model

Tessa Therapeutics enters alliance with Parker Institute for Cancer Immunotherapy

Cell Medica acquires Catapult Therapy TCR

Abide Therapeutics describes novel MGL/FAAH inhibitors

FDA approves Baxdela for ABSSSI

eFFECTOR Therapeutics identifies new MAP kinase signal-integrating kinase 1/2 inhibitors

Novel USP1 inhibitors identified at FORMA Therapeutics

Clovis Oncology presents positive topline data from phase III ARIEL3 study of rucaparib

ViiV Healthcare presents novel anti-HIV compounds

AstraZeneca, Cancer Research Technology patent GLS inhibitors

Narurapid and Narusus launched in Japan

Enzychem Lifesciences begins phase II trial of EC-18 in CIN

Novartis reports phase III data on RTH-258 in neovascular AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...